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Abstract 26 
PURPOSE: To investigate the influence of subretinal injection pressure on the 27 
microstructure of the retina in a monkey model. 28 
METHODS: After vitrectomy, balanced salt solution was injected subretinally into one 29 
eye each of four cynomolgus monkeys while controlling the injection pressure. Initially, 30 
a pressure of 2 psi was used, and this was gradually increased to determine the 31 
minimum required pressure. Subsequent injections were performed at two pressures: 32 
minimum (n=13) and high (n=6). To compare the influence of these injection pressures 33 
on retinal structure, optical coherence tomography (OCT) was performed before 34 
surgery and every week afterwards. The monkeys were euthanized and their eyes were 35 
enucleated at 1 or 6 weeks after the injections. The eyes were processed for light 36 
microscopy and transmission electron microscopy (TEM) as well as for TdT-mediated 37 
dUTP nick end labeling. 38 
RESULTS: The minimum pressure required to perform subretinal injection was 6 psi. 39 
After injection at this pressure, both OCT and microscopy showed that the retinal 40 
structure was well-preserved throughout the experimental period at all injection sites. 41 
Conversely, after injection at high pressure (20 psi) OCT images at all injection sites 42 
showed disruption of the ellipsoid zone (EZ) after 1 week. Microscopy indicated damage 43 
to the photoreceptor outer segment (OS) and stratification of the retinal pigment 44 
epithelium (RPE). After 6 weeks, OCT demonstrated that the EZ had become 45 
continuous and TEM confirmed that the OS and RPE had recovered. Photoreceptor 46 
apoptosis was absent after subretinal injection at both pressures. 47 
CONCLUSIONS: The retinal damage caused by subretinal injection increases 48 
depending on pressure, indicating that clinicians should perform subretinal injection at 49 
pressures as low as possible to ensure safety. 50 
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 51 
Introduction 52 
Surgical subretinal injections are used to displace subretinal hemorrhages [1-4], 53 
deliver gene therapy for retinal degeneration [5-8], perform macular translocation in 54 
patients with age-related macular degeneration [9,10], remove hard foveal exudates 55 
[11], and resolve diffuse diabetic macular edema during planned foveal detachment 56 
procedures [12,13]. To ensure that visual function is preserved after such procedures, 57 
clinicians must not damage the macula, and a safe and reliable technique for subretinal 58 
injection must therefore be developed. 59 
To deliver a subretinal injection to a patient with an attached retina, the 60 
injection pressure applied must exceed the adhesion force between the retina and 61 
retinal pigment epithelium (RPE) [14-16]. However, when a liquid is injected into the 62 
subretinal space, the stream may physically damage the structure of the outer retina 63 
and the RPE [17]. According to Poiseuille’s law, when a liquid of consistent viscosity is 64 
injected through a cannula with a consistent diameter, the flow rate is determined by the 65 
injection pressure [14]. However, the relationship between injection pressure and 66 
consequent retinal damage has not been sufficiently elucidated. 67 
On the basis of Laplace's law, patients with an attached retina require the 68 
highest injection pressure to initiate retinal detachment, and this required pressure 69 
decreases as the area of retinal detachment expands [18]. Therefore, in the present 70 
study, we investigated the effect of injection pressure, which is required to initiate retinal 71 
detachment, on the microstructure of the monkey retina using in vivo optical coherence 72 
tomography (OCT), light and electron microscopy, and TdT-dUTP terminal nick-end 73 
labeling (TUNEL). 74 
 75 
4 
Methods 76 
Ethics statement 77 
All animal experiments were reviewed and approved by the Institutional Animal 78 
Care and Use committee of Santen Pharmaceutical Co., Ltd. (approval no. 79 
DR-2016-0157). Male cynomolgus monkeys (Macaca fascicularis) aged 3–4 years and 80 
weighing 3.0–5.0 kg were purchased from Eve Bioscience Ltd. (Wakayama, Japan). 81 
The animal welfare and steps taken to ameliorate suffering were in accordance with 82 
Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan) and 83 
the recommendations of the Weatherall report on the use of non-human primates in 84 
research. The animals were housed individually in stainless steel cages (width: 47 cm, 85 
depth: 89 cm, height: 76 cm) at the animal facility of Santen Pharmaceutical Co., Ltd., 86 
where the environmental conditions were as follows: room temperature, 24°C; relative 87 
humidity, 60%; illumination, 12-hour lighting (7 a.m. to 7 p.m.) at 300 lux. They were fed 88 
100 g/animal/day of pellet food for monkeys (Monkey Bit; Nosan Corporation, 89 
Yokohama, Japan). Tap water from a feed-water nozzle was supplied ad libitum. During 90 
subretinal injection and OCT examination, monkeys were anesthetized by intramuscular 91 
injection of ketamine hydrochloride (10 mg/kg). Respiratory rate was monitored 92 
frequently and used to maintain adequate anesthesia using ketamine. Topical drops of 93 
oxybuprocaine were used for analgesia. Topical drops of 0.5% phenylephrine 94 
hydrochloride and 0.5% tropicamide were used for mydriasis. The monkeys were 95 
sedated and humanely euthanized by intravenous pentobarbital by a licensed 96 
veterinarian, either 1 week or 6 weeks after subretinal injections. Confirmation of death 97 
was determined by monitoring for absence of pulse, respiration, and neural reflexes. 98 
The eyes were enucleated immediately after euthanasia, either 1 week or 6 weeks after 99 
subretinal injections. 100 
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Subretinal injection with local removal of the internal 102 
limiting membrane 103 
In total, four monkeys were subjected to surgical subretinal injections in one 104 
eye. Specifically, transconjunctival, 25-gauge, 3-port, pars plana vitrectomies were 105 
performed using a commercially available vitrectomy machine (Accurus; Alcon 106 
Laboratories Inc., Fort Worth, TX, USA). Each injection site was at a mid-peripheral 107 
location within the eye. The internal limiting membrane (ILM) was then removed locally 108 
over approximately 1/4 of the disc area at each injection site, and balanced salt solution 109 
(BSS) was injected using a 38-gauge cannula (MedOne, Sarasota, FL, USA) until the 110 
area of retinal detachment had expanded to approximately one disc area (Fig 1), as 111 
described in our previous report [19]. By using this method, the BSS could be injected 112 
subretinally by placing the cannula tip in contact with the retinal nerve fiber layer 113 
exposed by ILM removal; thus, penetration of the retina with the cannula was 114 
unnecessary. 115 
 116 
Fig 1. Local removal of internal limiting membrane and subretinal injection of 117 
balanced salt solution. (A) Schematic drawing of local internal limiting membrane 118 
(ILM) removal showing the removed ILM (arrow), retina (asterisk), and intact ILM 119 
(arrowhead). (B) Schematic drawing of the subretinal injection procedure. Balanced salt 120 
solution (BSS) was injected with a 38-gauge cannula by placing the cannula tip in 121 
contact with the retinal nerve fiber layer. The arrow indicates the flow of the injected 122 
BSS; the asterisk and arrowhead indicate the retina and ILM, respectively. (C) Surgical 123 
photograph after local ILM removal. The arrow indicates the 38-gauge cannula; the 124 
arrowhead indicates the area of peeled ILM. (D) Surgical photograph during subretinal 125 
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injection. The arrow indicates the 38-gauge cannula; arrowheads indicate the area of 126 
retinal detachment due to subretinal injection of BSS. (E) Optical coherence 127 
tomography 30 minutes after subretinal injection. The asterisk indicates retinal 128 
detachment caused by the procedure. Scale bar = 200 μm. 129 
 130 
Investigation of minimum required injection pressure 131 
and establishment of experimental groups 132 
To ensure a constant pressure, subretinal injection was performed using the 133 
Viscous Fluid Control System (VFC; Alcon Laboratories Inc.), which allows the operator 134 
to raise the injection pressure from 2 psi to 80 psi in increments of 2 psi. Therefore, to 135 
identify the minimum required injection pressure, we began at 2 psi and increased the 136 
pressure until subretinal injection became possible. After the minimum required 137 
injection pressure was established (6 psi), we performed subretinal injection at this 138 
pressure at three or four sites in each eye (minimum-pressure group), for a total of 13 139 
sites (S1–S4 Figs). To compare the influence of the procedure on the retina at different 140 
pressures, we also performed high-pressure subretinal injection (20 psi) at one or two 141 
points in each eye (high-pressure group), for a total of six sites (S1–S4 Figs). We also 142 
performed local removal of the ILM, but not subretinal injection, at a total of three sites 143 
in two eyes (control group). We identified all injection sites after the surgery by using a 144 
recorded surgical video and conducted subsequent investigations. 145 
 146 
Optical coherence tomography 147 
OCT (Spectralis; Heidelberg Engineering GmbH, Heidelberg, Germany) was 148 
performed before surgery and every week after surgery until the 5th week. OCT images 149 
were first obtained 1 week after injection because this was the time point when 150 
7 
postoperative inflammation was reduced and clear OCT images were stably obtained in 151 
all cases. To improve reproducibility, the exact injection site and area of retinal 152 
detachment were identified based on the surgical video (Figure 1D) and infrared fundus 153 
images (Fig 2 and S1–S4 Figs). 154 
 155 
Fig 2. Optical coherence tomography images of monkey retina after subretinal 156 
injection of balanced salt solution. Optical coherence tomography (OCT) images of 157 
both control (no injection of balanced salt solution; BSS) and minimum-pressure (BSS 158 
injection at 6 psi) groups show a well-preserved retinal structure throughout the 159 
experimental period, including continuity of the ellipsoid zone (EZ) (A to F). OCT image 160 
from the high-pressure group (BSS injection at 20 psi) show EZ disruption (asterisk in 161 
G) at 1 week after the injection (G). At 3 weeks after the injection (H), OCT image from 162 
the high-pressure group shows partial recovery of the EZ (asterisk). The EZ finally 163 
became continuous (asterisk in I) at 5 weeks after the injection. Arrows in A, D, and G 164 
indicate the EZ. Scale bars = 200 μm. 165 
 166 
Light and transmission electron microscopy 167 
Two eyes, which were enucleated at either 1 week (S3 Fig) or 6 weeks (S1 Fig) 168 
after injections, were investigated with light and transmission electron microscopy 169 
(TEM). The eyes were fixed in a solution of 1% glutaraldehyde and 1% 170 
paraformaldehyde in phosphate-buffered saline. The specimens were post-fixed in 171 
veronal acetate buffer containing osmium tetroxide (1%), dehydrated in ethanol and 172 
water, and then embedded in Epon resin (Epon 812 Resin; TAAB Laboratories, 173 
Aldermaston, UK). The eyes were cut into 1-μm-thick sections, stained with toluidine 174 
blue, and observed by light microscopy. Tissue sections were prepared based on a 175 
surgical video and retinal blood vessels of enucleated eyeballs. For TEM, ultrathin 176 
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sections were cut from the Epon resin blocks and mounted on copper grids. The 177 
specimens were observed by using an H-7770 transmission electron microscope 178 
(Hitachi, Tokyo, Japan).  179 
 180 
TdT-dUTP terminal nick-end labeling 181 
Apoptosis of photoreceptor cells was investigated using TUNEL staining. For 182 
this analysis, two eyes were enucleated at 1 week (S4 Fig) and 6 weeks (S2 Fig) after 183 
injections and were fixed by using a mixture of methanol and formalin (Superfix; Kurabo, 184 
Osaka, Japan) at room temperature for the first 2.5 hours and at 4°C for the next 3 days. 185 
The eyes were then embedded in paraffin and cut into 3-μm sections. Tissue sections 186 
were prepared based on a surgical video and retinal blood vessels of enucleated 187 
eyeballs. TUNEL staining was performed by using an in situ apoptosis detection kit 188 
(Takara Bio Inc., Shiga, Japan), in accordance with the manufacturer’s protocol. 189 
 190 
Results 191 
Minimum pressure required for subretinal injection with 192 
local removal of ILM 193 
The minimum pressure required for subretinal injection was 6 psi, and the 194 
procedure was thus performed at this pressure in the minimum-pressure group. In the 195 
high-pressure group, subretinal injection was performed at 20 psi, based on the upper 196 
limit of the range of clinically-used injection pressures for gene therapy [15]. 197 
 198 
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Influence of minimum and high-pressure injection on 199 
the structure of the retina 200 
In vivo OCT examination revealed that there were no defects in the ellipsoid 201 
zone (EZ) at any of the 13 injection sites in the minimum-pressure group. Additionally, 202 
the retinal structure was identical between the minimum-pressure group and the control 203 
group, indicating that subretinal injection at 6 psi did not damage the retina (Fig 2A–2F 204 
and S1–S4 Figs). Conversely, in the high-pressure group, all six injection sites showed 205 
defects in the EZ at 1 week after injection (Fig 2G and S1–S4 Figs). These defects had 206 
begun to resolve at 3 weeks after injection (Fig 2H, S1 and S2 Figs) and had almost 207 
completely recovered at 5 weeks after injection (Fig 2I, S1 and S2 Figs). 208 
To further investigate our OCT findings that damaged EZ was observed 1 week 209 
after injection and had almost completely recovered by 5 weeks after injections (Fig 2G, 210 
Fig 2I, S1 and S2 Figs), eyeballs were enucleated at 1 or 6 weeks after surgery. We 211 
then examined the influence of subretinal injection on retinal structure by using light 212 
microscopy and TEM. In the minimum-pressure group, light microscopy showed normal 213 
retinal structure at both 1 and 6 weeks after injections (Fig 3C and 3D); this result was 214 
similar to that in the control group (Fig 3A and 3B). However, TEM analysis showed that 215 
the photoreceptor outer segment (OS) lengths were slightly shorter in the 216 
minimum-pressure group than in the control group at 1 week after injections (Fig 4A and 217 
4C). At 6 weeks after the injections, the OS lengths had recovered and were identical to 218 
that of the control group (Fig 4B and 4D). No RPE damage was observed by either light 219 
microscopy or TEM. In the high-pressure group, disappearance of the OS and 220 
stratification of the RPE were observed at 1 week after injections by both light 221 
microscopy and TEM (Fig 3E and 4E). These defects had partially resolved at 6 weeks 222 
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after injections, when reconstruction of the OS and flattening of the RPE were observed 223 
(Fig 3F and 4F). 224 
 225 
Fig 3. Light microscopy images of monkey retina after subretinal injection of 226 
balanced salt solution. The retinal structures of both the control (no injection of 227 
balanced salt solution; BSS) and the minimum-pressure (BSS injection at 6 psi) groups 228 
are well-preserved at 1 week (A and C) and 6 weeks (B and D) after injection. The high 229 
injection pressure group (BSS injection at 20 psi) shows thinning of the photoreceptor 230 
outer segment layer (OS, arrows in E) and thickening of the retinal pigment epithelium 231 
(RPE) layer (asterisk in E) at 1 week after injection (E), while the photoreceptor cells are 232 
well-preserved. At 6 weeks after injection, the high-pressure group shows restoration of 233 
the OS (arrows in F) and flattening of the RPE (asterisk in F). Scale bars = 100 μm. 234 
 235 
Fig 4. Transmission electron microscopy images of monkey retina after 236 
subretinal injection of balanced salt solution. Retinal structures of the control group 237 
(no injection of balanced salt solution; BSS) are well-preserved at 1 week (A) and 6 238 
weeks (B) after injection. The minimum-pressure group (BSS injection at 6 psi) shows a 239 
shorter photoreceptor outer segment (OS) than the control group at 1 week after 240 
injection (C, bidirectional arrow). The OS is restored at 6 weeks after injection (D, 241 
bidirectional arrow). The retinal pigment epithelium (RPE) is well-preserved throughout 242 
the experimental period (C and D). Conversely, the high-pressure group (BSS injection 243 
at 20 psi) shows degeneration of the OS (bidirectional arrow in E) and migration of RPE 244 
cells (arrows in E), leading to multiple RPE layers at 1 week after injection. 245 
Regeneration of the OS (bidirectional arrow in F) and flattening of the RPE (arrows in F) 246 
were observed at 6 weeks after the injection. Scale bars = 10 μm. 247 
 248 
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Photoreceptor cell death after subretinal injection at 6 249 
psi and 20 psi 250 
Light microscopy images with toluidine blue staining showed normal 251 
morphology of photoreceptor cells at 1 and 6 weeks after injections in both groups (Fig 252 
5A, 5D, 5G, and 5J). TUNEL staining showed no positive cells at either 1 or 6 weeks 253 
after injections in either group (Fig 5B, 5E, 5H, and 5K). Consistent with this result, TEM 254 
images showed that no chromatin condensation or nuclear fragmentation, which are 255 
characteristic features of apoptotic cell death, had occurred in the photoreceptor cells of 256 
either group at either time point (Fig 5C, 5F, 5I, and 5L). 257 
 258 
Fig 5. The effect of subretinal injection on photoreceptor cells. In the 259 
minimum-pressure (injection at 6 psi with balanced salt solution; BSS) and 260 
high-pressure (BSS injection at 20 psi) groups, both light microscopy images with 261 
toluidine blue staining and transmission electron microscopy (TEM) images show 262 
normal morphology of photoreceptor cells at 1 week (A, C, G and I) and 6 weeks (D, F, 263 
J, and L) after injection. TdT-dUTP terminal nick-end labeling (TUNEL) showed no 264 
positive photoreceptor cells in either the minimum-pressure or high-pressure groups 265 
throughout the experimental period (B, E, H, and K). Black and white scale bars = 20 266 
μm. Positive control of TUNEL staining is shown in S5 Fig. 267 
 268 
Discussion 269 
In the present study, we showed that the photoreceptor cells and the RPE of 270 
the monkey retina can be damaged by subretinal injection. To our knowledge, this is the 271 
first report to reveal that higher injection pressure causes greater retinal damage. Our 272 
12 
OCT (Fig 2D) and TEM (Fig 4C) results show that the retinal structure was relatively 273 
well-preserved when subretinal injection was applied at 6 psi. Conversely, severe EZ 274 
disruption was observed by OCT following subretinal injection at 20 psi (Fig 2G). 275 
However, the EZ had become continuous at 6 weeks after 20 psi subretinal injection 276 
(Fig 2I). Reflecting the OCT results, TEM images showed severe OS damage (Fig 4E) 277 
after 20 psi subretinal injection. However, as shown in Fig 5, the photoreceptor cells 278 
were intact; thus, the OS had recovered (Fig 4D and 4F) at 6 weeks after subretinal 279 
injection. These results are in agreement with the OS recovery observed after 280 
experimental short-term retinal detachment in monkey eye [20,21] and are similar to the 281 
OS recovery observed after retinal reattachment in patients with retinal detachment 282 
[22-24]. Considering that the severity of retinal damage was dependent on the injection 283 
pressure, subretinal injection should be performed at pressures as low as possible to 284 
ensure safety. 285 
The resistance associated with subretinal injection arises from the stiffness of 286 
the neural retina tissue and the adhesion force between the retina and the RPE; thus, 287 
the injection pressure must exceed this resistance [14,15]. Alternatively, the resistance 288 
caused by tissue stiffness can be eliminated by puncturing the neural retina with the 289 
injection cannula. However, this can damage the retina, RPE, and choroidal vessels, 290 
thereby causing serious complications, such as subretinal bleeding and choroidal 291 
neovascularization. Most tissue resistance within the neural retina originates from the 292 
ILM [25]. Therefore, to resolve the problems of subretinal injection, we recently 293 
attempted local removal of the ILM at the subretinal injection site [19]. This method 294 
enabled us to perform subretinal injection at a much lower pressure (6 psi) without 295 
puncturing the retina. Based on this finding, the present study investigated subretinal 296 
injection at the site of local ILM removal, revealing that subretinal injection could be 297 
performed at a pressure of 6 psi without puncturing the retina. These results are 298 
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consistent with our recent findings in the human eye [19] indicating that local removal of 299 
the ILM eliminates the resistance caused by the tissue stiffness of the neural retina, 300 
thus removing the need for retinal puncture. 301 
Although we focused on injection pressure in the present study, several other 302 
factors should be considered with respect to the retinal damage caused by subretinal 303 
injection. The first is the volume of the liquid to be injected under the retina, which differs 304 
depending on the aim and content of the subretinal injection (tPA [2,4,26], adenovirus 305 
vector [5,6,8], cell suspension [27-29], or BSS [9-13]). It has been reported that 306 
excessive stretching of the retina by the injected liquid can cause photoreceptor cell 307 
death by extension stress [15]. Secondly, the duration of retinal detachment should be 308 
considered. Several studies have reported that, in cases of long-term retinal 309 
detachment, apoptotic cell death of photoreceptor cells occurs due to a deficiency of 310 
nutrients from the choroid [20,30-32]. Thirdly, if the subretinal injection location includes 311 
the fovea, a macular hole may occur due to the injection pressure [6,7,33]. Finally, the 312 
presence or absence of adhesion between the retina and the RPE can influence the risk 313 
of retinal damage after subretinal injection. In cases of gene therapy or cell 314 
transplantation therapy to treat retinal degenerative diseases, subretinal injection must 315 
sometimes be performed at a site of retinal–RPE adhesion [5-8,15,34]. In such cases, 316 
the possibility of damaging the retina and RPE increases because higher injection 317 
pressures must be applied to exceed the adhesive force. 318 
This study has several important limitations. Firstly, it is unclear whether our 319 
results from monkey eyes can be generalized to humans. Secondly, although we 320 
revealed the effects of subretinal injection outside the macula, the effects of subfoveal 321 
injection on the fovea remain unknown. In the present study, we performed subretinal 322 
injections at several mid-peripheral locations at different injection pressures in the same 323 
eye because we wished to examine the influence of injection pressure on the retina by 324 
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establishing identical injection conditions. However, both the presence or absence of 325 
the foveal depression and the proportion of cone and rod photoreceptor cells differ 326 
between the fovea and midperiphery. Thirdly, although the approximate injection 327 
volumes were determined using the area of retinal detachment, the injected volumes 328 
were not necessarily the same at each injection site. In future studies, it will be 329 
necessary to adjust the injection volumes of all retinal detachments, which could be 330 
made possible by monitoring the injection volume with intraoperative OCT. Fourthly, the 331 
time point to evaluate photoreceptor cell death by TUNEL was limited to 1 week after 332 
injections due to the number of available monkeys. Considering the peak of TUNEL 333 
staining in previous reports on retinal detachment in animal models [35,36], evaluation 334 
at an earlier time point, such as 1–3 days after injection, will be necessary in future 335 
studies. Finally, the present study examined the influence of injection pressure on retina 336 
histology, but the influence of injection pressure on retinal function remains unknown. 337 
Future studies are needed to investigate functional changes in the retina after damage 338 
to the retinal outer layer and RPE as well as after their recovery. 339 
In summary, our results show that the photoreceptor layer and RPE can be 340 
damaged by subretinal injection and that the degree of damage depends on the 341 
injection pressure. To perform subretinal injection safely, clinicians must inject at the 342 
lowest possible pressure. 343 
 344 
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Supporting information 484 
S1 Fig. The sites of subretinal injections and the areas of retinal detachment in 485 
the monkey eye-1. A and B: The same fundus picture taken 3 weeks after subretinal 486 
injection. In B, the area of internal limiting membrane removal (a) and areas of retinal 487 
detachment due to subretinal injection (b–e) are illustrated as circles. Cross marks 488 
indicate the sites of subretinal injection at b-e. C–E: B-scan optical coherence 489 
tomography (OCT) images captured at “a”. F–H: B-scan OCT images captured at “b”. 490 
I–K: B-scan OCT images captured at “c”. L–N: B-scan OCT images captured at “d”. 491 
O–Q: B-scan OCT images captured at “e”. OCT images of both the control (removal of 492 
the ILM without subretinal injection of balanced salt solution; BSS) and 493 
minimum-pressure groups (BSS injection at 6 psi) show a well-preserved retinal 494 
structure, including continuity of the ellipsoid zone (EZ) throughout the experimental 495 
period (C–N). OCT images of the high-pressure group (BSS injection at 20 psi) show 496 
EZ disruption at 1 week after injection (asterisk in O). At 3 weeks after injection, OCT 497 
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images show partial recovery of the EZ (asterisk in P). The EZ finally became 498 
continuous at 5 weeks after injection (asterisk in Q). The eye was enucleated 6 weeks 499 
after subretinal injections and used for light and transmission electron microscopy. 500 
Scale bars = 200 μm. 501 
S2 Fig. The sites of subretinal injections and the areas of retinal detachment in 502 
the monkey eye-2. A and B: The same fundus picture taken 4 weeks after subretinal 503 
injection. In B, the areas of internal limiting membrane removal (a and b) and the areas 504 
of retinal detachment due to subretinal injection (c–f) are illustrated as circles. Cross 505 
marks indicate the sites of subretinal injection at c–f. C–E: B-scan optical coherence 506 
tomography (OCT) images captured at “a”. F–H: B-scan OCT images captured at “b”. 507 
I–K: B-scan OCT images captured at “c”. L–N: B-scan OCT images captured at “d”. 508 
O–Q: B-scan OCT images captured at “e”. R–T: B-scan OCT images captured at “f”. 509 
OCT images of both control (no injection of balanced salt solution; BSS) and 510 
minimum-pressure (BSS injection at 6 psi) groups show a well-preserved retinal 511 
structure throughout the experimental period, including continuity of the ellipsoid zone 512 
(EZ) (C to Q). OCT images of the high-pressure group (BSS injection at 20 psi) show EZ 513 
disruption at 1 week after injection (asterisk in R). The EZ became continuous at 3 and 514 
5 weeks after injection (asterisks in S and T). The eye was enucleated 6 weeks after 515 
subretinal injections and used for TdT-dUTP terminal nick-end labeling. Scale bars = 516 
200 μm. 517 
S3 Fig. The sites of subretinal injections and the areas of retinal detachment in 518 
the monkey eye-3. A and B: The same fundus picture taken 1 week after subretinal 519 
injection. In B, the areas of retinal detachment due to subretinal injection (a–e) are 520 
illustrated as circles. Cross marks indicate the sites of subretinal injection at a–e. C: 521 
B-scan optical coherence tomography (OCT) images captured at “a”. D: B-scan OCT 522 
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images captured at “b”. E: B-scan OCT images captured at “c”. F: B-scan OCT images 523 
captured at “d”. G: B-scan OCT images captured at “e”. OCT images of 524 
minimum-pressure (BSS injection at 6 psi) group show a well-preserved retinal structure 525 
at 1 week after injection, including continuity of the ellipsoid zone (EZ) (C–E). OCT 526 
images of the high-pressure group (BSS injection at 20 psi) show EZ disruption at 1 527 
week after injection (asterisks in F and G). The eye was enucleated 1 week after 528 
subretinal injections and used for light and transmission electron microscopy. Scale 529 
bars = 200 μm. 530 
S4 Fig. The sites of subretinal injections and the areas of retinal detachment in 531 
the monkey eye-4. A and B: The same fundus picture taken 1 week after subretinal 532 
injection. In B, the areas of retinal detachment due to subretinal injections (a–f) are 533 
illustrated as circles. Cross marks indicate the sites of subretinal injection at a–f. C: 534 
B-scan optical coherence tomography (OCT) images captured at “a”. D: B-scan OCT 535 
images captured at “b”. E: B-scan OCT images captured at “c”. F: B-scan OCT images 536 
captured at “d”. G: B-scan OCT images captured at “e”. H: B-scan OCT images 537 
captured at “f”. OCT images of minimum-pressure (BSS injection at 6 psi) group show a 538 
well-preserved retinal structure at 1 week after injection, including continuity of the 539 
ellipsoid zone (EZ) (C to F). OCT images of the high-pressure group (BSS injection at 540 
20 psi) show EZ disruption at 1 week after injection (asterisk in G and H). The eye was 541 
enucleated 1 week after subretinal injections and used for TdT-dUTP terminal nick-end 542 
labeling. Scale bars = 200 μm. 543 
S5 Fig. Positive control of TdT-dUTP terminal nick-end labeling. Lymph nodes 544 
taken simultaneously at the time of enucleation of monkey eyes were used as the 545 
positive control for TdT-dUTP terminal nick-end labeling (TUNEL). Arrows show 546 
TUNEL-positive cells. Scale bar = 20 μm. 547 
